Treatment(s) now being considered-Experimental drug Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Experimental drug Posts on Medivizor

Looking for patients with HER2-positive inoperable breast cancer to examine the efficacy and safety of antibody-drug conjugate SYD985

Posted by on Feb 3, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of the antibody-drug conjugate SYD985 for HER2-positive inoperable advanced breast cancer. The main outcome to be measured will be time from treatment until disease progression or the time taken for tumor growth or spread. This study is being conducted in Baltimore, Maryland, inthe United...

Read More

Retargeting: Treatment for metastatic HER2+ breast cancer that has progressed following targeted treatment

Posted by on Jul 18, 2015 in Breast cancer | 0 comments

In a nutshell The authors reviewed the benefits and safety of ado–trastuzumab emtansine (Kadcyla), a treatment for metastatic breast cancer (cancer that has spread to other areas of the body). Some background Human epidermal growth factor receptor 2 positive (HER2) breast cancer depends on HER2 for growth. Treatments that target the HER2...

Read More

Adding cetuximab (Erbitux) to brivanib alaniate (BMS-582664) does not improve patient quality of life

Posted by on Nov 24, 2014 in Colorectal cancer | 0 comments

In a nutshell The study investigated whether cetuximab (Erbitux) and brivanib alaniate (BMS-582664) can improve the quality of life of patients with chemotherapy-refractory metastatic colorectal cancer. Some background Some patients with colorectal cancer have chemotherapy-refractory metastatic cancer (the cancer does not respond to chemotherapy...

Read More

Eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers

Posted by on Apr 19, 2013 in Colorectal cancer | 0 comments

In a nutshell This phase III trial aims to determine the benefits of using the drugs eflornithine and sulindac (Clinoril) in the prevention of high risk adenomas and secondary colorectal cancers. Researchers will look at the number of recurrences over a 3 year period while administering the drugs. The details Patients previously treated for...

Read More

Preventing osteoporosis with Toremifene in men with prostate cancer treated with androgen deprivation therapy (ADT)

Posted by on Apr 18, 2013 in Prostate cancer | 0 comments

In a nutshell This article presents the results of a phase III clinical trial that evaluated the safety and efficacy of Toremifene (Acapodene) for lowering fracture risk in men with prostate cancer receiving androgen deprivation therapy (ADT). The risk of spinal fractures was significantly reduced in patients who received Toremifene. Some background...

Read More

Panitumumab combined with irinotecan as a treatment for metastatic colorecatal cancer without KRAS mutations

Posted by on Apr 7, 2013 in Colorectal cancer | 0 comments

In a nutshell This study looks at the use of panitumumab and irinotecan as a combination treatment in patients with KRAS wild-type (non-mutated) metastatic colorectal cancer which has continued to progress while on standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan, bevacizumab).   Some background Cancer cells can have...

Read More

Phase I and II clinical trial evaluating the combination of dabrafenib and trametinib for the treatment of patients with metastatic melanoma

Posted by on Apr 1, 2013 in Melanoma | 0 comments

In a nutshell This paper presents results from phase I and II clinical trials evaluating the safety and efficacy of two targeted therapies – dabrafenib and trametinib – given in combination for metastatic melanoma patients with BRAF mutations. Some background BRAF is a protein that plays a role in cell division and growth. About 50% of...

Read More

Phase III clinical trial for Trametinib shows improved survival in metastatic melanoma patients with BRAF mutations

Posted by on Apr 1, 2013 in Melanoma | 0 comments

In a nutshell This study presents the results of a phase III clinical trial evaluating the efficacy and safety of the drug trametinib for the treatment of metastatic melanoma patients with BRAF mutations. Some background BRAF is a protein from a chain of proteins in the cell called the MAP kinase pathway. These play a role in cell division and...

Read More